FGF21 and obesity due to melanocortin 4 receptor deficiency: Administration of FGF21 to rodents or non-human primates causes considerable pharmacological benefits on a cluster of obesity-related metabolic complications including a reduction in fat mass and alleviation of hyperglycemia, insulin resistance, and dyslipidemia [39].